Monday, April 20, 2020 5:17:20 PM
Yes.
No - FDA is not in the business of deciding whether patents are valid, or which ones will or could be infringed if they approve a generic, that's up to the courts. Everybody who is thinking the FDA could or would somehow reject or delay ANDAs in order to benefit AMRN to make this debacle "more fair" is barking up the wrong tree. Whether the FDA starts looking closer at the ANDAs now that AMRN lost in court or continues to dawdle because of the appeal I have no idea, but JT wouldn't be talking about injunctions and at-risk launches if he thought the FDA was going to just sit on it's hands until the appeal is decided. That said, with the news that AMRN's API suppliers were approached by generics and were rebuffed, I don't think a generic is actually going to be able to produce GV caps for the FDA to analyze anytime soon, and if generics cannot produce GV the FDA can't advance their ANDAs, so FDA will essentially just sit on it's hands, but not because they made a conscious decision to do so.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM